Evidence map›Paper›PMID 31272508›Full record

ArticleJournal of hematology & oncology2019

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.

Simona Piemontese, Ariane Boumendil, Myriam Labopin, Christoph Schmid, Fabio Ciceri, William Arcese, Yener Koc, Zafar Gulbas, Johanna Tischer, Benedetto Bruno and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 6 countries.

Simona PiemonteseHematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute, Milan, Italy. piemontese.simona@hsr.it.
Ariane BoumendilService d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Myriam LabopinService d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Christoph SchmidUniversitätsklinik Augsburg, II Medizinische Klinik, Augsburg, Germany.
Fabio CiceriHematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute, Milan, Italy.
William ArceseHematology Division-Stem Cell Transplant Unit, University of Rome Tor Vergata, Rome, Italy.
Yener KocStem Cell Transplant Unit, Medical Park Hospitals, Antalya, Turkey.
Zafar GulbasBone Marrow Transplantation Department, Anadolu Medical Center Hospital, Kocaeli, Turkey.
Johanna TischerLMU-University Hospital of Munich-Grosshadern, Medizinischen Klinik III, Munich, Germany.
Benedetto BrunoA.O.U Citta della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy.
Depei WuFirst Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
Didier BlaiseProgramme de Transplantation & Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France.
Dietrich BeelenDept. of Bone Marrow Transplantation, University Hospital, 45122, Essen, Germany.
Giuseppe IrreraCentro Unico Regionale Trapianti, Alberto Neri, Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Annalisa RuggeriDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, 00165, Roma, Italy.
Mohamed HouhouService d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Mohamad MohtyService d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Arnon NaglerHematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Sorbonne Université · FRCollegio Carlo Alberto · ITInserm · FRLMU Klinikum · DESoochow University · CNUniversity of Rome Tor Vergata · ITAntalya IVF · TREssen University Hospital · DETel Aviv University · ILUniversity Hospital Augsburg · DEVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs information on incidence, risk factors, and outcome of acute leukemia (AL) relapse after unmanipulated haploidentical stem cell transplantation (haplo-SCT) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

methodsAmong 1652 transplants performed for lymphoblastic and myeloid AL between 2007 and 2014, 587 patients (acute lymphoblastic leukemia (ALL) 131, acute myeloid leukemia (AML) 456) with detailed information were analyzed aiming to identify risk factors for post-transplant relapse and for overall survival (OS) after relapse.

resultsThe cumulative incidence of relapse at 3 years was 44% (35-53%) for ALL and 32% (27-36%) for AML (p = 0.023). In ALL, risk factors for relapse were disease status different from the first complete remission (CR1) at haplo-SCT (CR2 vs CR1: HR 2.85, p = 0.011; advanced vs CR1: HR 14.28, p < 0.0001) and male donor gender (HR 3.64, p = 0.0002), while in AML, risk factors were advanced disease at haplo-SCT (advanced vs CR1: HR 3.95, p < 0.0001) and comorbidities (HCT-CI) ≥ 3 (HR 1.75, p = 0.014). Transplants performed in more recent years were associated with lower relapse incidence (RI) in AML, but not in ALL (HR 0.91, p = 0.042). After relapse, median follow-up was 13 months (mos). OS at 1-year post relapse was 18%. Prognostic factors for superior OS after relapse were remission at time of haplo-SCT (CR vs advanced: HR 0.71, p = 0.028), time from transplant to relapse (≥ 5 mos vs < 5 mos: HR 0.530, p < 0.0001), and bone marrow as a stem cell source (peripheral blood (PB) vs bone marrow (BM): HR 1.473, p = 0.016).

conclusionsRisk factors for relapse after haploidentical transplantation were disease specific. Longer OS after relapse was achieved in particular by patients both in CR at haplo-SCT and relapsing more than 5 months after transplant (1-year OS 33%).

Indexed as

AdolescentAdultAgedFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesRisk FactorsSex FactorsSocieties, MedicalStem Cell TransplantationSurvival AnalysisLeukemia relapseSurvival after relapse

Identifiers

PMID31272508
PMCPMC6610936
OpenAlexW2955786636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.